KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Operating Margin: 2020-2025

Historic Operating Margin for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -3,327.57%.

  • Recursion Pharmaceuticals' Operating Margin fell 295048.00% to -3,327.57% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,656.17%, marking a year-over-year decrease of 105147.00%. This contributed to the annual value of -814.09% for FY2024, which is 2876.00% down from last year.
  • Recursion Pharmaceuticals' Operating Margin amounted to -3,327.57% in Q3 2025, which was down 262.97% from -916.75% recorded in Q2 2025.
  • Recursion Pharmaceuticals' Operating Margin's 5-year high stood at -377.10% during Q3 2024, with a 5-year trough of -4,042.41% in Q4 2024.
  • Over the past 3 years, Recursion Pharmaceuticals' median Operating Margin value was -908.36% (recorded in 2023), while the average stood at -1,320.77%.
  • In the last 5 years, Recursion Pharmaceuticals' Operating Margin soared by 2,938,181bps in 2021 and then crashed by 313,405bps in 2024.
  • Recursion Pharmaceuticals' Operating Margin (Quarterly) stood at -2,564.55% in 2021, then soared by 211,864bps to -445.91% in 2022, then plummeted by 46,246bps to -908.36% in 2023, then tumbled by 313,405bps to -4,042.41% in 2024, then plummeted by 295,048bps to -3,327.57% in 2025.
  • Its Operating Margin stands at -3,327.57% for Q3 2025, versus -916.75% for Q2 2025 and -1,297.85% for Q1 2025.